perhexiline has been researched along with Syndrome in 2 studies
Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.
Syndrome: A characteristic symptom complex.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome." | 9.19 | Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. ( Beadle, R; Brindley, G; Bruce, M; Cameron, D; Dawson, D; Frenneaux, M; Jagpal, B; Lang, C; Mckiddie, F; Nightingale, P; Rudd, A; Schwarz, K; Singh, S, 2014) |
| " In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome." | 5.19 | Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome. ( Beadle, R; Brindley, G; Bruce, M; Cameron, D; Dawson, D; Frenneaux, M; Jagpal, B; Lang, C; Mckiddie, F; Nightingale, P; Rudd, A; Schwarz, K; Singh, S, 2014) |
| "Several therapies commonly used for the treatment of acute heart failure syndromes (AHFS) present some well-known limitations and have been associated with an early increase in the risk of death." | 2.44 | Overview of emerging pharmacologic agents for acute heart failure syndromes. ( Böhm, M; De Luca, L; Dickstein, K; El-Banayosy, A; Filippatos, G; Gheorghiade, M; Mebazaa, A; Nieminen, M; Parissis, JT; Rhodes, A; Voors, AA; Zannad, F, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, S | 1 |
| Beadle, R | 1 |
| Cameron, D | 1 |
| Rudd, A | 1 |
| Bruce, M | 1 |
| Jagpal, B | 1 |
| Schwarz, K | 1 |
| Brindley, G | 1 |
| Mckiddie, F | 1 |
| Nightingale, P | 1 |
| Lang, C | 1 |
| Dawson, D | 1 |
| Frenneaux, M | 1 |
| De Luca, L | 1 |
| Mebazaa, A | 1 |
| Filippatos, G | 1 |
| Parissis, JT | 1 |
| Böhm, M | 1 |
| Voors, AA | 1 |
| Nieminen, M | 1 |
| Zannad, F | 1 |
| Rhodes, A | 1 |
| El-Banayosy, A | 1 |
| Dickstein, K | 1 |
| Gheorghiade, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomised Double Blind Placebo Controlled Trial of Perhexiline in Heart Failure With Preserved Ejection Fraction Syndrome (HFpEF)[NCT00839228] | Phase 2 | 70 participants (Anticipated) | Interventional | 2009-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for perhexiline and Syndrome
| Article | Year |
|---|---|
Overview of emerging pharmacologic agents for acute heart failure syndromes.
Topics: Adenosine; Cardiovascular Agents; Endothelin-1; Etiocholanolone; Heart Failure; Hemodynamics; Humans | 2008 |
1 trial available for perhexiline and Syndrome
| Article | Year |
|---|---|
Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome.
Topics: Cardiovascular Agents; Clinical Protocols; Double-Blind Method; Heart Failure; Humans; Outcome Asses | 2014 |